|
WO2021038062A1
|
|
T cell epitopes of hcmv and uses of thereof
|
|
EP3797777A1
|
|
Agent for the treatment of psoriasis
|
|
EP3797776A1
|
|
Cdk4/6 inhibitors for the treatment of psoriasis
|
|
EP3778923A1
|
|
Method for classifying a patient's responsiveness to immune checkpoint inhibitor therapy
|
|
DE102019120337A1
|
|
Method for classifying the risk of developing cervical intraepithelial neoplasia
|
|
DE102019120336A1
|
|
Procedure for classifying the risk of developing HPV persistence
|
|
DE102019117837A1
|
|
Prophylaxis and treatment of an infection of the cervix with human papillomavirus (HPV)
|
|
US2019376035A1
|
|
Granulocytic myeloid-derived suppressor cells (GR-MDSC) accumulate in human breastmilk
|
|
DE102019112244A1
|
|
Peptides for use in the therapy or prophylaxis of Herpesviridae infections
|
|
DE102019108825A1
|
|
Compounds and methods for treating diseases of the liver
|
|
EP3689367A1
|
|
Improved means and methods to treat diabetes
|
|
DE102018126242A1
|
|
Spacers for an endodontic instrument
|
|
EP3539562A1
|
|
Immunotherapeutic peptides
|
|
DE102018105511A1
|
|
Device for the production of a plasma for wound treatment and system with such a device
|
|
DE102017126191A1
|
|
Method for the diagnosis of a blood coagulation disorder
|
|
DE102017110935A1
|
|
Anti-inflammatory high-purity oligosaccharides
|
|
DE102017110933A1
|
|
Immunostimulant high purity oligosaccharides
|
|
EP3401683A1
|
|
Diagnosing metabolic disease by the use of a biomarker
|
|
DE102017109723A1
|
|
Medical device for laying a catheter
|
|
EP3398963A1
|
|
Chemically modified mrna for use in the treatment of a disease associated with the cftr gene
|
